Cat.No. : CSC-SC002757-H1 Host Cell: HEK293
| Cat. No. | CSC-SC002757-H1 |
| Description | This cell line is engineered to stably overexpress human CD52 molecule (CD52). |
| Gene | CD52 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | HEK293 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: The Human CD52 Stable Cell Line - HEK293 is an invaluable tool for the development of chimeric antigen receptor (CAR) T cell therapies. It allows researchers to test the specificity and efficacy of CAR-T cells designed to target CD52-expressing cancer cells. By evaluating the cytotoxic activity of CAR-T cells against this cell line, researchers can optimize the design of CAR-T therapies and predict their potential effectiveness in clinical settings.
A: Utilizing the Human CD52 Stable Cell Line - HEK293 in animal models enables researchers to study the biodistribution and pharmacokinetics of CD52-targeting therapeutics. By introducing labeled versions of these therapeutics and tracking their accumulation in tissues expressing the CD52 antigen, researchers can gain insights into the drug's distribution, clearance, and potential off-target effects.
A: Researchers can manipulate the expression levels of CD52 in the Human CD52 Stable Cell Line - HEK293 to investigate how these levels affect the cell line's sensitivity to immunotherapies. This can be achieved through the use of shRNA knockdown, CRISPR/Cas9 gene editing, or overexpression techniques. By comparing the responses of cells with varying CD52 expression levels, researchers can determine the optimal therapeutic window and the potential impact of antigen expression variability on treatment outcomes.
A: By using the Human CD52 Stable Cell Line - HEK293, researchers can explore the functional role of the CD52 antigen in immune cell interactions. This cell line can be co-cultured with immune cells expressing CD52-binding molecules to study the effects on cell signaling, activation, and immune response modulation. Such studies can provide insights into the physiological and pathological roles of CD52 in the immune system.
A: The Human CD52 Stable Cell Line - HEK293 has been engineered to stably express the human CD52 antigen on its cell surface. This feature is particularly beneficial for researchers interested in evaluating the binding and internalization of ADCs, as CD52 is a common target for such therapeutics. The cell line provides a controlled environment to assess the specificity and cytotoxicity of ADCs, enabling the study of the drug's mechanism of action at a cellular level and informing the design of more effective targeted therapies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human CD52 Stable Cell Line - HEK293 consistently expresses CD52, which is crucial for reliable experimental outcomes in studies focused on this glycoprotein. This consistency ensures reproducible results, which are essential for validating the role of CD52 in immune regulation and potential therapeutic applications.
The HEK293 cells are known for their robust growth and high viability, characteristics that extend to the Human CD52 Stable Cell Line - HEK293. This enhanced cell viability is critical for conducting prolonged studies without the risk of losing cell integrity or function.
We can use the Human CD52 Stable Cell Line - HEK293 to perform comparative studies between different cell lines expressing CD52 or between cells with and without CD52 expression. This comparison is vital for understanding the unique roles and effects of CD52 in various cellular environments.
The Human CD52 Stable Cell Line - HEK293 is particularly suited for high-throughput screening applications. This capability allows for the rapid testing of multiple compounds or conditions affecting CD52 function, streamlining the discovery process in drug development and mechanistic studies of CD52.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
